Esperion Theraptc (ESPR)

$3.79 +0.01 (0.26%)
Market Cap 874.97M
Revenue (ttm) 332.31M
Net Income (ttm) -51.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.57%
Debt to Equity Ratio -0.34
Volume 4,155,049
Avg Vol 7,290,948
Day's Range N/A - N/A
Shares Out 239.06M
Stochastic %K 79%
Beta 1.01
Analysts Strong Sell
Price Target $6.46

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
Gregg617
Gregg617 Dec. 4 at 9:10 PM
$ESPR Most normal people would be throttling down after that big run not me, I’ve got my foot on the pedal to the floor, sold some March $2.50 100% profit to get more 40% more Jan$3, higher strike closer dated this is your captain speaking “Brace for impact”
1 · Reply
Albertowest
Albertowest Dec. 4 at 9:01 PM
$ESPR "How to steal cheap shares" Chapter 10,981
1 · Reply
profitsforall
profitsforall Dec. 4 at 8:38 PM
$ESPR Again: Schwab at the opening had 2.4 MILLION shares available to short. At 3:34P today Schwab has Limited (616,539) shares available to short.. Total volume 3.9 million shares traded so far.
1 · Reply
Hawaiianinvesta
Hawaiianinvesta Dec. 4 at 8:25 PM
$ESPR yes $HIMS holders now is the time to get in, if you love money you will love this stock
1 · Reply
minnesotafarmcountry
minnesotafarmcountry Dec. 4 at 8:13 PM
$ESPR 🤬
0 · Reply
HowDidThatGetInThere
HowDidThatGetInThere Dec. 4 at 8:10 PM
$ESPR They always gotta crash it end of day.
1 · Reply
mquilty123
mquilty123 Dec. 4 at 7:37 PM
$ESPR
0 · Reply
jacksparo
jacksparo Dec. 4 at 7:32 PM
$GUTS $ADCT $BULL $ESPR I am looking into new trade opportunities Let’s us see what we have in 2026/27 Journey 📈📈✅📈📈✅! I will share my trade ideas via the email / Telegram as usual 📈📈📈!
2 · Reply
simbha
simbha Dec. 4 at 7:30 PM
$ESPR Interesting day:
0 · Reply
drive_in_buffet
drive_in_buffet Dec. 4 at 7:28 PM
$ESPR
1 · Reply
Latest News on ESPR
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 4:03 PM EST - 14 days ago

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 18, 2025, 7:00 AM EST - 16 days ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

Nov 12, 2025, 10:16 AM EST - 22 days ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CCCC CWST INSP MNDY SITM

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Nov 11, 2025, 9:31 PM EST - 22 days ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Nov 10, 2025, 7:24 AM EST - 24 days ago

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 6, 2025, 4:30 PM EST - 27 days ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:06 PM EST - 4 weeks ago

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Oct 8, 2025, 8:01 AM EDT - 2 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

JOBY PENG

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 9:29 PM EDT - 2 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Esperion Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 2 months ago

Esperion Announces Proposed Public Offering of Common Stock

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Oct 3, 2025, 8:00 AM EDT - 2 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 19, 2025, 8:00 AM EDT - 2 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 10:17 PM EDT - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Top 2 Health Care Stocks That May Plunge This Month

Sep 5, 2025, 10:39 AM EDT - 3 months ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 29, 2025, 8:00 AM EDT - 3 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Esperion (ESPR) Q2 Revenue Jumps 12%

Aug 5, 2025, 11:57 PM EDT - 4 months ago

Esperion (ESPR) Q2 Revenue Jumps 12%

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:10 AM EDT - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:00 AM EDT - 4 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 22, 2025, 8:00 AM EDT - 4 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 5 months ago

Esperion Appoints Craig Thompson to Board of Directors

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

Jun 14, 2025, 7:03 AM EDT - 6 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 12, 2025, 8:00 AM EDT - 7 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 9, 2025, 8:00 AM EDT - 7 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 8, 2025, 6:30 AM EDT - 7 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

May 6, 2025, 10:49 AM EDT - 7 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Esperion to Participate in The Citizens Life Sciences Conference

Apr 25, 2025, 8:00 AM EDT - 7 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 10, 2025, 8:00 AM EDT - 8 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 10:34 AM EST - 9 months ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 4, 2025, 6:00 AM EST - 9 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Mar 3, 2025, 8:00 AM EST - 9 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Feb 18, 2025, 8:00 AM EST - 10 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Dec 8, 2024, 7:43 AM EST - 1 year ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13, 2024, 2:08 AM EST - 1 year ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 1:35 PM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion to Report Third Quarter 2024 Financial Results on November 7

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Aug 19, 2024, 9:10 AM EDT - 1 year ago

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Gregg617
Gregg617 Dec. 4 at 9:10 PM
$ESPR Most normal people would be throttling down after that big run not me, I’ve got my foot on the pedal to the floor, sold some March $2.50 100% profit to get more 40% more Jan$3, higher strike closer dated this is your captain speaking “Brace for impact”
1 · Reply
Albertowest
Albertowest Dec. 4 at 9:01 PM
$ESPR "How to steal cheap shares" Chapter 10,981
1 · Reply
profitsforall
profitsforall Dec. 4 at 8:38 PM
$ESPR Again: Schwab at the opening had 2.4 MILLION shares available to short. At 3:34P today Schwab has Limited (616,539) shares available to short.. Total volume 3.9 million shares traded so far.
1 · Reply
Hawaiianinvesta
Hawaiianinvesta Dec. 4 at 8:25 PM
$ESPR yes $HIMS holders now is the time to get in, if you love money you will love this stock
1 · Reply
minnesotafarmcountry
minnesotafarmcountry Dec. 4 at 8:13 PM
$ESPR 🤬
0 · Reply
HowDidThatGetInThere
HowDidThatGetInThere Dec. 4 at 8:10 PM
$ESPR They always gotta crash it end of day.
1 · Reply
mquilty123
mquilty123 Dec. 4 at 7:37 PM
$ESPR
0 · Reply
jacksparo
jacksparo Dec. 4 at 7:32 PM
$GUTS $ADCT $BULL $ESPR I am looking into new trade opportunities Let’s us see what we have in 2026/27 Journey 📈📈✅📈📈✅! I will share my trade ideas via the email / Telegram as usual 📈📈📈!
2 · Reply
simbha
simbha Dec. 4 at 7:30 PM
$ESPR Interesting day:
0 · Reply
drive_in_buffet
drive_in_buffet Dec. 4 at 7:28 PM
$ESPR
1 · Reply
Baruke
Baruke Dec. 4 at 7:24 PM
$ESPR did someone say break the 4th wall?
0 · Reply
Heliosphere
Heliosphere Dec. 4 at 7:02 PM
$ESPR Break the $4 wall forever!!!
1 · Reply
gbuster57
gbuster57 Dec. 4 at 6:45 PM
$ESPR This two-candle pattern is a powerful bullish reversal signal that typically appears after a clear downtrend. First Candle: A small bearish (red) candle, indicating that sellers were in control for that specific period. The small body suggests selling pressure might be weakening. Second Candle: A large bullish (green) candle that completely "engulfs" or covers the entire real body of the first candle. This candle shows that buyers have decisively taken control, often opening lower than the previous close but closing significantly higher than the previous open. The appearance of this pattern shows a significant shift in market sentiment, where buying pressure has overpowered selling pressure.
2 · Reply
omar_progressivetrading
omar_progressivetrading Dec. 4 at 6:35 PM
$ESPR — What a fun day watching everyone try to figure out what printed yesterday… Some got a headache, others were asking every AI on the planet, and only one person spotted it. Congrats @Miro_cruz 👏🏼 Micro Bullish Engulfing Candle… on low volume. A rare combination, and a powerful one inside a revamping phase. The best hour is approaching, and I’m very excited to see what kind of revamp this turns into. The data has never looked stronger… the structure is tightening… and Santa is officially coming to town. You better behave well, Moon Kids! to The Moon & Beyond! 🫡 🌖
3 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Dec. 4 at 6:32 PM
$HIMS you should own $ESPR stock. Buy every week some before 1st qtr earnings.
0 · Reply
simbha
simbha Dec. 4 at 5:56 PM
$ESPR Repatha and Praluent in Kaiser listings:
1 · Reply
djohnson591
djohnson591 Dec. 4 at 5:22 PM
$ESPR Kaiser had BA on a few of their smaller plans in the past (Gov Employee, POS, some PPO, ect). It was recently added to their Medicare coverage.
0 · Reply
simbha
simbha Dec. 4 at 5:21 PM
$ESPR Kaiser 2025-2026 Formulary:
1 · Reply
djohnson591
djohnson591 Dec. 4 at 5:16 PM
$ESPR Market makers will eat those stop losses up
0 · Reply
simbha
simbha Dec. 4 at 5:16 PM
$ESPR Kaiser 2023 BA :
0 · Reply
Lskynrd1
Lskynrd1 Dec. 4 at 5:04 PM
$ESPR I really think 26 we will be trading at much higher SPs. All this good news we're getting and idl to get political here but they are predicting an economic boom next year and with all money already committed we've never anything like it i believe them. So put it all together and it says ESPR $25 in 2026
0 · Reply
theDeathStar
theDeathStar Dec. 4 at 4:57 PM
$ESPR looks like it’s setting up to make another Run at $4 next week.
0 · Reply